Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus: A 3-Year Post-Marketing Surveillance Study

被引：0
|
作者：
Fumiko Yamamoto
Yuriko Unno
Tomoo Okamura
Rie Ikeda
Kaori Ochiai
Naoyuki Hayashi
机构：
[1] Nippon Boehringer Ingelheim Co.,Medicine Division
[2] Ltd.,PMS Division
[3] EPS Corporation,undefined
来源：
Diabetes Therapy | 2020年 / 11卷
关键词：
DPP-4 inhibitor; Japanese; Linagliptin; Long-term; Post-marketing surveillance; Type 2 diabetes mellitus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：107 / 117
页数：10
相关论文
共 50 条
  • [21] Real-world evidence for long-term safety and effectiveness of ipragliflozin in treatment-naive versus non-naive Japanese patients with type 2 diabetes mellitus: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM)
    Maegawa, Hiroshi
    Tobe, Kazuyuki
    Nakamura, Ichiro
    Uno, Satoshi
    DIABETOLOGY INTERNATIONAL, 2021, 12 (04) : 430 - 444
  • [22] Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study
    Kaku, Kohei
    Chin, Rina
    Naito, Yusuke
    Iliev, Hristo
    Ikeda, Rie
    Ochiai, Kaori
    Yasui, Atsutaka
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (02) : 211 - 221
  • [23] Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study
    Shingaki, Tomotaka
    Taki, Kentaro
    Koyanagi, Momoha
    Nagaoka, Soshi
    Yoshizawa, Kenichi
    Oki, Norika
    Yoshikawa, Aki
    Imaoka, Takeshi
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (06) : 947 - 958
  • [24] Safety and effectiveness of empagliflozin and linagliptin fixed-dose combination therapy in Japanese patients with type 2 diabetes: final results of a one-year post-marketing surveillance study
    Inagaki, Nobuya
    Nishimoto, Takaaki
    Nishiya, Yoichi
    Nitta, Daisuke
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (02) : 153 - 163
  • [25] Long-term safety and effectiveness of omalizumab in Japanese paediatric patients with severe allergic asthma: A post-marketing surveillance
    Nakamura, N.
    Kashitani, Y.
    Yoshisue, H.
    Nagasaki, M.
    Sasajima, T.
    ALLERGY, 2020, 75 : 364 - 365
  • [26] The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study
    Yasuo Terauchi
    Makiko Usami
    Tomoyuki Inoue
    Advances in Therapy, 2022, 39 : 2873 - 2888
  • [27] Real-world evidence for long-term safety and effectiveness of ipragliflozin in treatment-naïve versus non-naïve Japanese patients with type 2 diabetes mellitus: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM)
    Hiroshi Maegawa
    Kazuyuki Tobe
    Ichiro Nakamura
    Satoshi Uno
    Diabetology International, 2021, 12 : 430 - 444
  • [28] The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study
    Terauchi, Yasuo
    Usami, Makiko
    Inoue, Tomoyuki
    ADVANCES IN THERAPY, 2022, 39 (06) : 2873 - 2888
  • [29] Long-term tolerability and effectiveness of raltegravir in Japanese patients: Results from post-marketing surveillance
    Kuroishi, Naho
    Watananbe, Asuka
    Sakuma, Ryuta
    Ruzicka, Daniel J.
    Hara, Mitsuyoshi
    PLOS ONE, 2019, 14 (01):
  • [30] Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes
    Araki, E.
    Kawamori, R.
    Inagaki, N.
    Watada, H.
    Hayashi, N.
    Horie, Y.
    Sarashina, A.
    Thiemann, S.
    von Eynatten, M.
    Dugi, K.
    Woerle, H. -J.
    DIABETES OBESITY & METABOLISM, 2013, 15 (04): : 364 - 371
12345